Predict your next investment

HEALTHCARE | Drug Manufacturing / Vitamins, Supplements & Nutraceuticals
protherainc.com

See what CB Insights has to offer

Stage

Acquired | Acquired

About ProThera

ProThera manufactures an extensive selection of nutraceutical products for distribution by healthcare professionals. ProThera's Klaire Labs division offers hypoallergenic probiotics, enzymes, and specialty formulas. Products are designed for clinical applications based on formulation experience.In July 2013, ProThera was acquired by Soho Flordis International. The valuation of ProThera was undisclosed. Other terms of the deal were not released.

ProThera Headquarter Location

10439 Double R Blvd

Reno, Nevada, 89521,

United States

775-850-8800

Latest ProThera News

Eisai forges CNS alliance with UK’s Wren Therapeutics

Dec 1, 2020

December 1, 2020 Japanese drugmaker Eisai has teamed up with UK biotech Wren Therapeutics on an R&D programme seeking drugs for neurodegenerative disorders. The two companies will focus their efforts on alpha-synuclein, a pathway that has been implicated in disorders such as dementia with Lewy bodies (DLB) and Parkinson’s disease (PD). DLB and PD are both so-called synucleinopathies, diseases that are characterised by mutations in the SNCA gene coding for alpha-synuclein, leading to the production of misfolded, toxic forms of the protein that clump together and are thought to damage nerve cells. Wren – a spinout from the universities of Cambridge in the UK and Lund in Sweden – has developed a drug discovery platform that can be used to screen small-molecule drugs to see if they can bind to misfolded proteins and correct their structure, preventing them from aggregating. It’s a similar concept to interfering with the aggregation of beta-amyloid to form neurotoxic plaques in diseases like Alzheimer’s disease – another of Wren’s research targets. Under the terms of the agreement, Cambridge-based Wren’s “network kinetics” platform will be deployed alongside Eisai’s drug discovery expertise in neurodegenerative disorders. Eisai has a long heritage in this area, having been involved in the development of well-established Alzheimer’s drug Aricept (donepezil) and various other drugs for epilepsy, with a late-stage pipeline that includes Biogen-partnered anti-amyloid drug aducanumab , currently under review by the FDA. “Synucleinopathies such as dementia with Lewy bodies and Parkinson’s disease represent a significant unmet medical need due to the lack of any effective disease-modifying treatments,” said Dr Teiji Kimura, who heads up drug discovery in Eisai’s neurology division. “The accumulation of alpha-synuclein oligomers with protein misfolding is an important hallmark of these diseases,” he added. Last summer, Wren raised 23 million in first-round financing to advance its internal R&D in the area of protein-misfolding diseases. Other companies are also targeting alpha-synuclein, although Eisai and Wren are unusual in that they are seeking small-molecule candidates. Rivals include Roche and Prothera, which have an antibody in late-stage testing, as well as AstraZeneca/Takeda, Biogen, Lundbeck, AbbVie/BioArctic and Denali. Roche licensed the antibody – called prasinezumab – from Prothera in a $600 million deal that dates back several years. Earlier this year however, the programme had a setback when a phase 2 trial in PD missed the mark. The partners said the data showed some signs of efficacy, and prasinezumab is now heading for a phase 2b trial as an add-on therapy to standard levodopa therapy in PD. Biogen has an antibody candidate called cinpanemab (BIIB054) in the phase 2 SPARK trial, due to generate results next year, while Lundbeck started a phase 1 trial in 2018 of Lu AF82422, another antibody, that could read out before year-end. AZ and Takeda started a first phase 1 trial of their MEDI 1341 antibody in 2017, adding a second earlier this year that is due to run until 2022, while AbbVie’s ABBV-0805 cleared a phase 1 trial but seems to have been sidelined for strategic reasons. Denali’s project is earlier in development. Its preclinical candidate ATV:aSyn is a bispecific antibody designed to penetrate the central nervous system more effectively, with one end targeting alpha-synuclein and another targeting a transporter in the blood-brain barrier. Don't miss your daily pharmaphorum news.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ProThera

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ProThera is included in 1 Expert Collection, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

628 items

ProThera Patents

ProThera has filed 12 patents.

The 3 most popular patent topics include:

  • Microbiology
  • Abdominal pain
  • Autoimmune diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/14/2018

8/3/2021

Bacteriology, Bacterial diseases, Small nuclear RNA, Microbiology, Digestive system

Grant

Application Date

5/14/2018

Grant Date

8/3/2021

Title

Related Topics

Bacteriology, Bacterial diseases, Small nuclear RNA, Microbiology, Digestive system

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.